What do systematic reviews say?

Aciclovir (oral or intravenous) for treatment vs placebo

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  Two studies. Median time to total healing was shorter for patients receiving oral or intravenous aciclovir than placebo: median of 8 days versus 21 days, P = 0.01 (Shepp 1985); 13.9 days versus 20.7 days, P = 0.08…
  2 studies
  GRADE not reported

Aciclovir (oral or intravenous) for treatment vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
  0 studies
  No studies found

Aciclovir (oral or intravenous) for treatment vs placebo

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  Two studies. Statistically significant difference in median duration of virus shedding in favour of intravenous aciclovir (2.5 days versus 17.0 days, P = 0.0002; Meyers 1982) and oral aciclovir (2 days versus more than…
  2 studies
  GRADE not reported

Aciclovir (oral or intravenous) for treatment vs placebo

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  Time to first decrease in pain was significantly shorter in favour of oral aciclovir (median 3 days versus 16 days, P = 0.04; Shepp 1985). Time to complete resolution of pain was shorter with oral aciclovir than…
  2 studies
  GRADE not reported

Aciclovir (oral or intravenous) for treatment vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
  0 studies
  No studies found

Aciclovir (oral or intravenous) for treatment vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
  0 studies
  No studies found

Aciclovir (oral or intravenous) for treatment vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
  0 studies
  No studies found

Aciclovir (oral or intravenous) for treatment vs placebo

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  Adverse effects were assessed in both studies. For intravenous aciclovir the most commonly reported adverse effect was a reaction at the injection site (8 (16%) aciclovir versus 3 (7%) placebo; all patients, n = 97);…
  2 studies
  GRADE not reported

Aciclovir (oral or intravenous) for treatment vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
  0 studies
  No studies found